Imricor and Philips Launch Commercial iMR Lab Solution

Key points

• Commercial launch with Philips: Combined iMR lab solution for MR-guided cardiac interventions
• Integrated, purpose-built solution: Combines Philips' 1.5T BlueSeal MR platform with Imricor's systems
• Supports adoption of iMR-guided cardiac care: Designed for cardiac electrophysiology procedures

Full summary

Imricor Medical Systems, Inc. (ASX: IMR) has announced the launch of a new Interventional MR (iMR) lab solution in collaboration with Royal Philips. The combined iMR lab solution integrates Philips' high-performance 1.5 Tesla (1.5T) MRI platform and interventional workflow capabilities with Imricor's portfolio of MR-compatible systems and consumables. The initial configuration is designed to enable iMR-guided workflows for cardiac interventions, including cardiac electrophysiology procedures. The solution is immediately available in CE-marked markets and certain configurations are also available in the United States, with additional configurations expected to become available subject to regulatory clearances.